Synlogic reports second quarter 2023 financial results and provides business update

Recent milestones include initiation of the pivotal phase 3 trial, synpheny-3, and receipt of fast track designation for labafenogene marselecobac as a potential treatment for pku recent milestones include initiation of the pivotal phase 3 trial, synpheny-3, and receipt of fast track designation for labafenogene marselecobac as a potential treatment for pku
SYBX Ratings Summary
SYBX Quant Ranking